Partial
Mostly Aligned
Patient Risk:
Info
Summary
Only one of the provided atomic claims (cardiovascular risk reduction indication for adults with elevated triglycerides with specified risk profiles) is supported by the supplied label text. Multiple other atomic claims (mechanism of action specifics, dosing frequency, capsule availability, and multiple non-label cost/discount/generic claims) are not supported or cannot be verified from the provided prescribing information excerpt.
Category Scores
Accurate Statements
Use of VASCEPA (icosapent ethyl) to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides (≥150 mg/dL) who have established cardiovascular disease or diabetes mellitus plus 2 or more additional risk factors (as an adjunct to maximally tolerated statin therapy).
Supported by '1 INDICATIONS AND USAGE' first bullet: adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated TG (≥150 mg/dL) with established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors.
Unsupported Statements
Vascepa is a prescription medication used to lower triglyceride levels in the blood.
The provided label excerpt includes an indication to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia, but the claim is generalized and is not explicitly stated in the excerpt as a general-purpose 'lower triglycerides in the blood' statement.
Vascepa (icosapent ethyl) works by inhibiting the production of triglycerides in the liver.
The label excerpt lists mechanisms including decreased lipogenesis in the liver and inhibition of DGAT, but it does not explicitly state 'inhibiting the production of triglycerides' as the mechanism in those exact terms.
Vascepa is available in 1-gram capsules.
Label excerpt supports that 1-gram capsules exist, but the atomic claim does not specify the exact label-described capsule forms/strengths context. (Overall marked unsupported for strict atomic verification across the provided excerpt because the evaluation framework requires direct support for the atomic claim as stated.)
Vascepa is typically taken once or twice daily.
No dosing frequency is provided in the supplied label excerpt (only dosage forms/strengths are shown).
The average cost of Vascepa 1-gram capsules is around $1,200 for a 30-day supply (as stated in the text).
Cost/price information is not included in the supplied prescribing information excerpt.
Prices for Vascepa can range from $900 to $1,500 or more depending on pharmacy and location (as stated in the text).
Price range information is not included in the supplied prescribing information excerpt.
Amarin offers a patient assistance program for eligible patients that can help them save up to $1,000 per year (as stated in the text).
Patient assistance program details and savings amounts are not included in the supplied prescribing information excerpt.
To qualify for Amarin's patient assistance program, patients must meet certain income and insurance requirements (as stated in the text).
Eligibility criteria for a patient assistance program are not included in the supplied prescribing information excerpt.
CVS, Walgreens, and Rite Aid offer discounts on Vascepa (as stated in the text).
Retail pharmacy discount claims are not included in the supplied prescribing information excerpt.
Pharmacy discounts for Vascepa can range from 10% to 50% off the retail price (as stated in the text).
Discount percentages are not included in the supplied prescribing information excerpt.
Coupon programs including the Vascepa Savings Card can provide savings of up to $100 per month (as stated in the text).
Coupon/savings card and savings amounts are not included in the supplied prescribing information excerpt.
The text states that there are no generic alternatives to Vascepa available.
Generic availability statements are not included in the supplied prescribing information excerpt.
The text states that some pharmacies may offer a generic version of the medication at a lower cost.
Generic availability/cost statements are not included in the supplied prescribing information excerpt.
If you qualify for the Amarin patient assistance program, the text states you could save up to $1,000 per year, or around $83 per month.
Patient assistance savings amounts are not included in the supplied prescribing information excerpt.
If you use a pharmacy discount program, the text states you could save up to 50% off the retail price, or around $600 per month.
Discount savings and monthly dollar estimates are not included in the supplied prescribing information excerpt.
If you use a coupon program, the text states you could save up to $100 per month.
Coupon savings and monthly dollar estimates are not included in the supplied prescribing information excerpt.
The text states that opting for a generic version could save up to 50% off the retail price, or around $600 per month.
Generic substitution savings estimates are not included in the supplied prescribing information excerpt.
Contradictions
Important Omissions
The provided labeling excerpt also includes a second indication ('adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia') and a limitation of use regarding pancreatitis risk; these are not addressed in the AI content shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The only label-supported claim concerns an on-label cardiovascular risk reduction indication. However, several other AI-provided claims relate to dosing frequency and non-label financial programs; these could mislead patients if followed, but the excerpt provided contains no dosing frequency or safety details to verify those statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Multiple atomic claims (dosing frequency, mechanism wording specificity, dosing form availability framing, and all pricing/patient assistance/discount/generic availability claims) are not supported by the supplied FDA label excerpt.
Suggested Improvement
Limit statements to what is explicitly supported in the provided 'INDICATIONS AND USAGE', 'DOSAGE FORMS AND STRENGTHS', and 'Mechanism of Action' excerpt; remove or clearly separate non-label cost/discount/generic availability claims, and avoid asserting dosing frequency not present in the provided label text.